![]() | ![]() |
Formats:
|
||||||||||||||||
Cardiotoxicity of Ma Huang/Caffeine or Ephedrine/Caffeine in a Rodent Model System 1 National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA 2 Battelle, Columbus, Ohio 43201, USA Address correspondence to: Dr. June K. Dunnick, P. O. Box 12233, Research Triangle Park, NC 27709, USA; e-mail: dunnickj/at/niehs.nih.gov The publisher's final edited version of this article is available at Toxicol Pathol.Abstract Ma Huang (equivalent to 0, 12.5, 25, or 50 mg/kg ephedrine) or ephedrine (0, 6.25, 12.5, 25 mg/kg) were administered as one bolus oral dose to male F344 rats with and without caffeine. The herbal medicine Ma Huang (ephedra) in combination with caffeine caused rapid clinical signs of toxicity including salivation, hyperactivity, ataxia, and eventually lethargy, and failure to respond to stimuli. When this syndrome of clinical signs emerged, animals were moribund sacrificed, and a histological analysis for heart lesions performed. Cardiotoxicity included hemorrhage, necrosis, and degeneration in the ventricles or interventricular septum within 2–4 hours after treatment with Ma Huang (ephedra)/caffeine or ephedrine (the principal active component in Ma Huang)/caffeine. There was a steep dose response curve for cardiotoxicity with minimal toxicity seen at levels of Ma Huang (equivalent to 12.5 mg/kg ephedrine) with caffeine. However, cardiotoxic lesions occurred in 28% of animals with Ma Huang dosages equivalent to 25 mg/kg ephedrine with 15 or 30 mg/kg caffeine, and in 90% of animals at Ma Huang exposures equivalent to 50 mg/kg ephedrine with 15 or 30 mg/kg caffeine. Cardiotoxic lesions occurred in 47% of animals in the 25 mg/kg ephedrine groups with caffeine at 7.25, 15, or 30 mg/kg. There was no statistical difference in the occurrence of cardiotoxic lesions when 15 or 30 mg/kg caffeine was combined with Ma Huang equivalent to 25 or 50 mg/kg ephedrine; likewise there was no statistical difference in the occurrence of cardiotoxic lesions when 7.25, 15, or 30 mg/kg caffeine was combined with 25 mg/kg ephedrine. These results show that the cardiotoxic effects of the herbal medicine, Ma Huang, are similar to that of ephedrine, the principal active ingredient in the herbal medicine. The combination of Ma Huang or ephedrine with caffeine enhanced the cardiotoxicity over that with the herbal medicine or the active ingredient alone. Keywords: Cardiotoxicity, Ma Huang, ephedra, ephedrine, caffeine Introduction Ephedrine and caffeine are the primary active components in dietary supplements that contain Ma Huang (ephedra) and guarana-derived caffeine (Csajka et al., 2005). Use of these herbal medicines has been linked to cardiotoxicity in humans (Astrup et al., 1991; McBride et al., 2004; Naik and Freudenberger, 2004; Persky et al., 2004; Haller et al., 2005b; Peters et al., 2005; Vukovich et al., 2005). Ma Huang dietary supplements are regulated under the 1994 Dietary Supplement and Health Education Act (DSHEA), an act which does not require that manufacturers of a dietary supplement provide safety data to the U.S. Food and Drug Administration before marketing the product (U.S. Food and Drug Administration, 1995). However, based on accumulated data on the cardiotoxicty of ephedra containing supplements, the U.S. Food and Drug Administration issued a rule banning the sale of these supplements in 2004 (U.S. Food and Drug Administration, 2004), In 2005, U.S. courts (U.S. Federal District Court, 2005) notes that additional “dose specific analysis” is need to fully understand the adverse effects of ephedrine-containing products. We have previously reported that the combination treatment of ephedrine and caffeine rapidly caused cardiotoxicity in rats (Howden et al., 2005; Nyska et al., 2005). The treatment-related changes included increases in heart rate, blood pressure, and temperature (Howden et al., 2005), and interstitial hemorrhage, with degeneration of myofibers in the subendocardial myocardium of the ventricles and interventricular septum (Nyska et al., 2005). In this study, we compare the cardiotoxicity of ephedrine and caffeine to that of herbal medicine Ma Huang (ephedra) and caffeine in the F344 rat based on clinical and histopathologic findings. The cardiotoxic effects are reported for Ma Huang (ephedra) and ephedrine dosages that are 10–20 times human oral ephedrine exposure levels based on a mg/m2 body surface area comparison. Methods and Materials Chemicals and Dose Formulation Dosing solutions consisted of ephedrine hydrochloride (Sigma-Aldrich, St. Louis, Mo; >99% L-ephedrine), ephedrine hydrochloride-plus-caffeine (Pfaltz and Bauer, Waterbury, CT), Ma Huang (Jinke Group, USA, Inc.), Ma Huang-plus-caffeine, or caffeine prepared in 0.5% methyl-cellulose (Figure 1
Animals and Study Design Male F344/N rats (Taconic Laboratory, Germantown, NY), 15–16 weeks of age, received a single oral gavage dose of the stock solutions at 5 ml/kg to 20 animals per treatment group. Rats were housed 5 per cage in polycarbonate cages and fed NTP-2000 wafer feed (Zeigler Brothers, Inc., Gardners, PA) ad libitum. At approximately 11 pm on the day prior to dosing, feed was removed so that animals would be dosed on an empty stomach (~8–10 am), and then returned to cages containing feed once the dose had been administered. Animals were observed continuously after dosing for clinical signs of toxicity, and clinical signs of toxicity were recorded at 2 and 4 hours after dosing or immediately prior to moribund sacrifice. The experiment was conducted at an AAALAC-accredited facility, and animal handling and husbandry met all NIH guidelines (Institute of Laboratory Animal Resources, 1996). Pathology Procedures Terminally sacrificed (~4 hours after dosing) and moribund animals were sacrificed with CO2. At necropsy, all organs and tissues were examined for grossly visible lesions. The heart was fixed in 10% neutral-buffered formalin, processed, and trimmed into 2 longitudinal halves; both sides were embedded in paraffin, sectioned to a thickness of 4–6 μm, and stained with hematoxylin and eosin (H&E) for microscopic examination. Sections of the heart contained muscle of both ventricles, interventricular septum and atria (Morawietz et al., 2004). The criteria for grading lesion severity used was as previously reported (Howden et al., 2005; Nyska et al., 2005), which, in turn were consistent with NTP criteria for non-neoplastic lesions (Shackelford et al., 2002). As stated by Shackelford et al., a grade of Minimal (+1) consists of a lesion that affects up to 10% of a tissue and can vary from being barely noticeable to one considered minor enough to warrant the lowest assignable grade, a grade of Mild (+2) consists of a lesion that affects 11–20% of a tissue and is noticeable but not a prominent feature of the tissue, while a grade of Moderate (+3) consists of a lesion that affects 21–40% of a tissue and is a prominent feature of the tissue. Statistical Methods Cochran-Mantel-Haenszel (CMH) trend tests were performed to relate the level of ephedrine or Ma Huang (or ephedrine equivalents) with the lesion incidence at each level of caffeine (Fleiss, 1973). CMH tests were also performed for caffeine at each level of ephedrine and Ma Huang administered. Fisher’s exact tests were used to compare each dosed group with its corresponding control group (Gart et al., 1979). Results Mortality and Clinical Observations Clinical signs of toxicity were seen in rats receiving a combination of ephedrine/caffeine or Ma Huang/caffeine (Figure 2
Treatment-Related Cardiac Lesions Treatment-related cardiotoxicity was observed in most of the moribund sacrificed animals and consisted of hemorrhage, degeneration, and necrosis (Tables 1 and 2. These lesions were of minimal severity and a magnification of 10× or greater was generally needed to see these changes (Figure 3
Hemorrhage (Figure 3B Necrosis (Figure 3D Occasionally, a myocardial fiber adjacent to the cluster of nuclear fragments was hyalinized and deeply eosinophilic indicating it was undergoing coagulative necrosis. The prominent distinguishing feature of necrosis was the presence of diffusely scattered fragmented nuclei with little or no accompanying inflammatory cell reaction. In contrast, cardiomyopathy consisted of a smaller number of larger foci most of which, except for those consisting of early coagulation necrosis of myocardial fibers, contained prominent inflammatory cell infiltrate. The exact cell undergoing nuclear fragmentation could not be determined with certainty. In some cases it appeared to be myocardial cells, and in other cases possibly interstitial cells, endothelial cells, or inflammatory cells located in the space between adjacent fibers. The hemorrhage seen in treated animals could have been an indicator of endothelial damage. Treatment-related cardiotoxic lesions occurred in the 25 mg/kg ephedrine groups with caffeine (Table 1), in the 1250 mg/kg Ma Huang (equivalent to 50 mg/kg ephedrine) groups with or without caffeine, and in the 625 mg/kg Ma Huang (equivalent ot 25 mg/kg ephedrine) groups with caffeine (Table 2). In addition to the treatment-related lesions, there was a background of cardiomyopathy (Figure 3A There was no statistical difference in the occurrence of cardiotoxic lesions between 15 and 30 mg/kg caffeine combined with Ma Huang equivalent to 25 or 50 mg/kg ephedrine (p > .60); likewise, there was no statistical difference in the occurrence of cardiotoxic lesions between 7.25, 15, and 30 mg/kg caffeine combined with 25 mg/kg ephedrine (p > .30). However, when used in combination with Ma Huang equivalent to 25 or 40 mg/kg ephedrine, 15 or 30 mg/kg caffeine significantly increased (p < 0.05) the occurrence of cardiotoxic lesions compared to when no caffeine was added. Likewise, in combination with 25 mg/kg ephedrine, 30 mg/kg caffeine significantly (p < 0.05) increased the occurrence of cardiotoxic lesions compared to when no caffeine was added. Discussion In this study, we compare the cardiotoxic effects of ephedrine and caffeine with those of Ma Huang and caffeine. Clinical signs of toxicity in the male F344 rat began within 1 hour of exposure to ephedrine/caffeine or Ma Huang/caffeine, and included ataxia, hyperactivity, and eventually failure to respond to stimuli, resulting in moribund sacrifice. While clinical toxicity occurred with ephedrine alone (25 mg/kg), the magnitude of the response increased with the addition of caffeine. With Ma Huang (equivalent to 25 or 50 mg/kg of ephedrine), the magnitude of clinical toxicity also increased with the addition of caffeine. The lowest dose of Ma Huang alone to cause clinical toxicity leading to moribund sacrifice was equivalent to an exposure of 25 mg/kg ephedrine. Ma Huang and ephedrine cardiotoxicity, with and without caffeine, induced cardiotoxic lesions of hemorrhage, necrosis, and degeneration. The treatment-related lesions were of minimal severity regardless of dose level. This is consistent with previous studies where we found that ephedrine/caffeine related heart toxicity (as measured by functional changes) is not always accompanied by the presence of severe cardiotoxic lesions (Howden et al., 2005). The addition of caffeine enhanced the incidence of treatment-related cardiotoxic lesions of the herbal medicine or ephedrine, although caffeine alone did not induce significant cardiotoxic lesions. Treatment-related histopathologic findings of minimal severity were considered significant. Very small lesions may significantly affect the function of the heart and produce profound clinical signs (and even death). It is not known whether these treatment-related heart lesions are secondary to myocardial ischemia or hyperthermia or other clinical toxicity (Howden et al., 2005), or a primary effect of the test articles. Treatment-related heart lesions were found primarily in animals showing clinical signs of toxicity followed by moribund sacrifice, and not in the ephedrine/Ma Huang groups of rats living until terminal sacrifice (~4 hours after treatment). Treatment-related heart lesions were not found in any control rats in the ephedrine study and in only 1 control rat (hemorrhage) in the Ma-Huang study. This suggests a very strong connection between the clinical signs of lethargy and recumbancy and the myocardial degeneration and necrosis. Ephedra sinica extract commonly used in dietary supplements consists of ephedrine, pseudoephedrine, methyle-phedrine, norpseudoephedrine, and norephedrine, of which ephedrine is the principal alkaloid component. A typical ephedrine-alkaloid containing dietary supplement dose contains ~20 mg ephedrine and ~200 mg of guarana-derived caffeine (Haller et al., 2004; Jacob et al., 2004). Ephedrine alkaloids are rapidly absorbed with maximum plasma concentration (tmax) occurring within 2.4 hours and an ephedrine plasma half-life of ~6.1 hours (Wilkinson and Beckett, 1968; White et al., 1997; Haller et al., 2002b). A typical human ephedrine/caffeine dosage, is ~0.3 mg ephedrine/kg body weight (11 mg/m2 body surface area) (Nyska et al., 2005). In this study, ephedrine cardiotoxicity was studied over a broader dose range than in our previous study where the exposure level of 25 mg/kg (~130 mg/m2 body surface area) is ~12 times human exposure based on a mg/m2 body surface area comparison (Nyska et al., 2005). Ephedrine doses of 6.25, 12, or 25 mg/kg are ~3–12 times human exposure levels (mg/m2 body surface area comparison). Ephedrine plasma levels in humans taking a typical ephedrine-containing herbal medicine are reported to be approximately 60–150 ng/ml plasma at 1–2 hours after drug administration (Vanakoski et al., 1993; Haller et al., 2002a; Csajka et al., 2005; Haller et al., 2005a, 2005b). Analysis of a few 25 mg/kg ephedrine rat plasma samples 1–2 hours after administration showed ephedrine plasma levels of ~1000–2000 ng/ml (National Toxicology Program, 2006). More complete toxicokinetic studies are required to compare human and rat ephedrine plasma levels and parameters. One hypothesis for the mechanism of ephedrine and caffeine cardiotoxicity is that these chemicals work together to cause rapid death by increasing calcium levels and thereby altering electrical and contraction properties of the heart (Figure 4
Acknowledgments This research was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. We thank Battelle Columbus where the animals for this study were dosed and housed under NIEHS contract N01-ES-65406. The statistical analysis was conducted under NIEHS contract N01-ES-55547 to Constella Group, Durham, NC 27713. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Br J Clin Pharmacol. 2005 Mar; 59(3):335-45.
[Br J Clin Pharmacol. 2005]Metabolism. 1991 Mar; 40(3):323-9.
[Metabolism. 1991]JAMA. 2004 Jan 14; 291(2):216-21.
[JAMA. 2004]Ann Pharmacother. 2004 Mar; 38(3):400-3.
[Ann Pharmacother. 2004]Br J Clin Pharmacol. 2004 May; 57(5):552-62.
[Br J Clin Pharmacol. 2004]Am J Physiol Heart Circ Physiol. 2005 May; 288(5):H2219-24.
[Am J Physiol Heart Circ Physiol. 2005]Toxicol Sci. 2005 Feb; 83(2):388-96.
[Toxicol Sci. 2005]Am J Physiol Heart Circ Physiol. 2005 May; 288(5):H2219-24.
[Am J Physiol Heart Circ Physiol. 2005]Toxicol Sci. 2005 Feb; 83(2):388-96.
[Toxicol Sci. 2005]Toxicol Pathol. 2002 Jan-Feb; 30(1):93-6.
[Toxicol Pathol. 2002]J Natl Cancer Inst. 1979 Apr; 62(4):957-74.
[J Natl Cancer Inst. 1979]Am J Physiol Heart Circ Physiol. 2005 May; 288(5):H2219-24.
[Am J Physiol Heart Circ Physiol. 2005]Am J Physiol Heart Circ Physiol. 2005 May; 288(5):H2219-24.
[Am J Physiol Heart Circ Physiol. 2005]J Anal Toxicol. 2004 Apr; 28(3):145-51.
[J Anal Toxicol. 2004]J Anal Toxicol. 2004 Apr; 28(3):152-9.
[J Anal Toxicol. 2004]J Pharm Sci. 1968 Nov; 57(11):1933-8.
[J Pharm Sci. 1968]J Clin Pharmacol. 1997 Feb; 37(2):116-22.
[J Clin Pharmacol. 1997]Clin Pharmacol Ther. 2002 Jun; 71(6):421-32.
[Clin Pharmacol Ther. 2002]Toxicol Sci. 2005 Feb; 83(2):388-96.
[Toxicol Sci. 2005]Eur J Clin Pharmacol. 1993; 45(4):377-81.
[Eur J Clin Pharmacol. 1993]Clin Pharmacol Ther. 2002 Jun; 71(6):421-32.
[Clin Pharmacol Ther. 2002]Br J Clin Pharmacol. 2005 Mar; 59(3):335-45.
[Br J Clin Pharmacol. 2005]Am J Med. 2005 Sep; 118(9):998-1003.
[Am J Med. 2005]Clin Pharmacol Ther. 2005 Jun; 77(6):560-71.
[Clin Pharmacol Ther. 2005]Biochem Pharmacol. 1999 Sep 1; 58(5):807-10.
[Biochem Pharmacol. 1999]J Biol Chem. 2001 Jan 12; 276(2):1063-70.
[J Biol Chem. 2001]J Biol Chem. 2001 May 11; 276(19):15945-52.
[J Biol Chem. 2001]J Biol Chem. 2001 Jun 8; 276(23):20186-9.
[J Biol Chem. 2001]J Biol Chem. 2001 Feb 23; 276(8):5613-21.
[J Biol Chem. 2001]